ReviewArchives of Razi Institute2025
Immune Boosters and Immunotherapy in Allergic Diseases and in Cancer Management.
Review in Archives of Razi Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergy and cancer are immune-mediated diseases that present substantial clinical challenges, and immunotherapy, which exploits the immune system for therapeutic intervention, holds immense potential in their management. This review scrutinises the immunotherapeutic landscape of allergic diseases and cancer, emphasising their shared immunological underpinnings and therapeutic implications. Allergy manifests as exaggerated immune responses to innocuous antigens, culminating in inflammation and tissue damage. The therapeutic objective in the context of allergy is to induce immune tolerance to allergens, thereby alleviating symptoms and improving disease outcomes. Conversely, cancer employs multifaceted immune evasion mechanisms to evade immunosurveillance and propagate malignancy. Immunotherapeutic strategies in cancer endeavour to reinvigorate antitumor immunity and eradicate neoplastic cells. A notable development in this field is the emergence of immune checkpoint inhibitors as a cornerstone in cancer immunotherapy, unleashing the immune system's potential to recognise and eliminate malignant cells. This review elucidates the intricate immunological mechanisms underlying allergy and cancer pathogenesis and delineates the diverse immunotherapeutic strategies employed in each context. It underscores the convergence of immunological principles and clinical applications in shaping the therapeutic landscape of allergic diseases and cancer. By synthesising fundamental immunology with clinical insights, immunotherapy offers transformative prospects for personalised medicine, as evidenced by recent advancements, including immune checkpoint blockade and adoptive cell therapy, which have revolutionized the treatment paradigm in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.